Which has better earnings and valuation, COGT or SMMT?

Summit Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is COGT or SMMT more profitable?

Cogent Biosciences' return on equity of -84.47% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -84.47% -47.72% Summit Therapeutics N/A -168.94% -141.92%

Cogent Biosciences (COGT) Competitors

$28.38 -1.40 (-4.70%)

As of 02:16 PM Eastern

Compare

COGT vs. EXEL, ASND, SMMT, BBIO, and HALO

Should you buy Cogent Biosciences stock or one of its competitors? Cogent Biosciences's main competitors and comparable companies include Exelixis (EXEL), Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cogent Biosciences compare to Exelixis?

Cogent Biosciences (NASDAQ:COGT) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, Exelixis had 23 more articles in the media than Cogent Biosciences. MarketBeat recorded 24 mentions for Exelixis and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.82 beat Exelixis' score of 0.38 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cogent Biosciences	Very Positive
Exelixis	Neutral

85.3% of Exelixis shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Exelixis has a net margin of 35.33% compared to Cogent Biosciences' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Exelixis	35.33%	42.17%	31.76%

Cogent Biosciences currently has a consensus price target of $51.56, suggesting a potential upside of 73.12%. Exelixis has a consensus price target of $50.79, suggesting a potential downside of 15.10%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Cogent Biosciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

Cogent Biosciences has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Exelixis has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Exelixis	$2.32B	6.39	$782.57M	$3.18	18.81

Summary

Exelixis beats Cogent Biosciences on 10 of the 15 factors compared between the two stocks.

How does Cogent Biosciences compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Ascendis Pharma A/S has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

Ascendis Pharma A/S has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.38	-$258M	$12.89	17.61
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Ascendis Pharma A/S has a net margin of 70.99% compared to Cogent Biosciences' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Cogent Biosciences	N/A	-84.47%	-47.72%

Ascendis Pharma A/S presently has a consensus price target of $313.21, suggesting a potential upside of 37.98%. Cogent Biosciences has a consensus price target of $51.56, suggesting a potential upside of 73.12%. Given Cogent Biosciences' higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Ascendis Pharma A/S and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.82 beat Ascendis Pharma A/S's score of 0.56 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Ascendis Pharma A/S	Positive
Cogent Biosciences	Very Positive

Summary

Ascendis Pharma A/S beats Cogent Biosciences on 11 of the 13 factors compared between the two stocks.

How does Cogent Biosciences compare to Summit Therapeutics?

Cogent Biosciences (NASDAQ:COGT) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Cogent Biosciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, indicating that its share price is 251% less volatile than the broader market.

Cogent Biosciences currently has a consensus target price of $51.56, suggesting a potential upside of 73.12%. Summit Therapeutics has a consensus target price of $28.61, suggesting a potential upside of 67.00%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

4.6% of Summit Therapeutics shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Summit Therapeutics had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Summit Therapeutics and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.82 beat Summit Therapeutics' score of 0.71 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cogent Biosciences	Very Positive
Summit Therapeutics	Positive

Summit Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Cogent Biosciences' return on equity of -84.47% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Summit Therapeutics	N/A	-168.94%	-141.92%

Summary

Cogent Biosciences beats Summit Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Cogent Biosciences compare to BridgeBio Pharma?

Cogent Biosciences (NASDAQ:COGT) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

99.9% of BridgeBio Pharma shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 16 more articles in the media than Cogent Biosciences. MarketBeat recorded 17 mentions for BridgeBio Pharma and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.82 beat BridgeBio Pharma's score of 0.47 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cogent Biosciences	Very Positive
BridgeBio Pharma	Neutral

Cogent Biosciences presently has a consensus target price of $51.56, suggesting a potential upside of 73.12%. BridgeBio Pharma has a consensus target price of $105.42, suggesting a potential upside of 60.34%. Given Cogent Biosciences' higher possible upside, equities analysts clearly believe Cogent Biosciences is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83

Cogent Biosciences has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Cogent Biosciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Cogent Biosciences has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
BridgeBio Pharma	$502.08M	25.60	-$724.93M	-$3.57	N/A

Summary

Cogent Biosciences and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Halozyme Therapeutics has a net margin of 24.86% compared to Cogent Biosciences' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Cogent Biosciences	N/A	-84.47%	-47.72%

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Halozyme Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Halozyme Therapeutics currently has a consensus target price of $94.00, indicating a potential downside of 15.38%. Cogent Biosciences has a consensus target price of $51.56, indicating a potential upside of 73.12%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Halozyme Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	9.03	$316.89M	$3.35	33.16
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

In the previous week, Halozyme Therapeutics had 22 more articles in the media than Cogent Biosciences. MarketBeat recorded 23 mentions for Halozyme Therapeutics and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.82 beat Halozyme Therapeutics' score of 0.80 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Halozyme Therapeutics	Positive
Cogent Biosciences	Very Positive

Summary

Halozyme Therapeutics beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks.

Get Cogent Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COGT vs. The Competition

Export

Metric	Cogent Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.90B	$3.84B	$7.18B	$13.17B
Dividend Yield	N/A	3.65%	2.52%	20.73%
P/E Ratio	-13.06	13.34	275.58	25.75
Price / Sales	N/A	1,184.41	619.65	102.39
Price / Cash	N/A	39.46	27.30	36.12
Price / Book	7.34	16.97	10.71	6.04
Net Income	-$328.94M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-7.18%	-3.73%	-2.47%	-2.69%
1 Month Performance	-15.59%	-11.23%	-5.97%	-4.89%
1 Year Performance	74.07%	10.47%	4.73%	-2.27%

Cogent Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COGT Cogent Biosciences	2.8507 of 5 stars	$28.38 -4.7%	$51.56 +81.7%	+83.0%	$4.92B	N/A	N/A	258
EXEL Exelixis	2.3662 of 5 stars	$58.85 +0.8%	$50.29 -14.6%	+56.8%	$14.58B	$2.44B	18.51	1,077	Analyst Revision
ASND Ascendis Pharma A/S	4.8099 of 5 stars	$228.03 +0.1%	$310.75 +36.3%	+8.3%	$14.21B	$814.57M	17.69	1,189	Analyst Upgrade
SMMT Summit Therapeutics	2.2984 of 5 stars	$17.27 +3.1%	$28.61 +65.6%	-19.8%	$13.37B	N/A	N/A	265	Upcoming Earnings
BBIO BridgeBio Pharma	3.9202 of 5 stars	$66.14 -1.7%	$102.61 +55.1%	+18.5%	$13.15B	$713.07M	N/A	839

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COGT) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cogent Biosciences (COGT) Competitors

COGT vs. EXEL, ASND, SMMT, BBIO, and HALO

How does Cogent Biosciences compare to Exelixis?

Summary

How does Cogent Biosciences compare to Ascendis Pharma A/S?

Summary

How does Cogent Biosciences compare to Summit Therapeutics?

Summary

How does Cogent Biosciences compare to BridgeBio Pharma?

Summary

How does Cogent Biosciences compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cogent Biosciences (COGT) Competitors

COGT vs. EXEL, ASND, SMMT, BBIO, and HALO

How does Cogent Biosciences compare to Exelixis?

Does the media favor COGT or EXEL?

Do insiders & institutionals have more ownership in COGT or EXEL?

Is COGT or EXEL more profitable?

Do analysts recommend COGT or EXEL?

Which has more risk & volatility, COGT or EXEL?

Which has better valuation and earnings, COGT or EXEL?

Summary

How does Cogent Biosciences compare to Ascendis Pharma A/S?

Which has more volatility and risk, ASND or COGT?

Which has stronger earnings & valuation, ASND or COGT?

Is ASND or COGT more profitable?

Do analysts recommend ASND or COGT?

Does the media prefer ASND or COGT?

Summary

How does Cogent Biosciences compare to Summit Therapeutics?

Which has more risk and volatility, COGT or SMMT?

Do analysts recommend COGT or SMMT?

Do institutionals & insiders hold more shares of COGT or SMMT?

Does the media refer more to COGT or SMMT?

Which has better earnings and valuation, COGT or SMMT?

Is COGT or SMMT more profitable?

Summary

How does Cogent Biosciences compare to BridgeBio Pharma?

Do institutionals and insiders hold more shares of COGT or BBIO?

Does the media prefer COGT or BBIO?

Do analysts recommend COGT or BBIO?

Is COGT or BBIO more profitable?

Which has more volatility and risk, COGT or BBIO?

Which has higher valuation and earnings, COGT or BBIO?

Summary

How does Cogent Biosciences compare to Halozyme Therapeutics?

Is HALO or COGT more profitable?

Do institutionals and insiders believe in HALO or COGT?

Which has more risk and volatility, HALO or COGT?

Do analysts rate HALO or COGT?

Which has higher valuation and earnings, HALO or COGT?

Does the media refer more to HALO or COGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools